| Title |
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951
|
|---|---|
| Published in |
Haematologica, July 2017
|
| DOI | 10.3324/haematol.2017.165845 |
| Pubmed ID | |
| Authors |
Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Françoise Mazingue, Geneviève Plat, Karima Yakouben, Anne Uyttebroeck, Patrick Lutz, Vitor Costa, Nicolas Sirvent, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Philip Maes, Claire Hoyoux, Hélène Cavé, Pierre Rohrlich, Yves Bertrand, Yves Benoit |
| Abstract |
Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The value of asparaginase was further addressed in a group of non-very high risk patients by comparing a prolonged (long-asparaginase) versus standard (short-asparaginase) native E.coli asparaginase treatment through a randomized question as part of the phase III 58951 trial of the European Organisation for Research and Treatment of Cancer Children's Leukemia Group. The main endpoint was disease-free survival. Overall, 1,552 patients were randomly assigned to long-asparaginase (775 patients) or short-asparaginase (777 patients). Patients with grade≥2 allergy to native E.coli asparaginase were switched to equivalent doses of Erwinia or pegylated E.coli asparaginase. The 8-year disease-free survival rate (±standard error) was 87.0+/-1.3% in the long-asparaginase and 84.4±1.4% in the short-asparaginase group (hazard ratio:0.87, P=0.33) and the 8-year overall survival rate was 92.6&+/-1.0% and 91.3+/-1.2% respectively (hazard ratio:0.89, P=0.53). An exploratory analysis suggested that the impact of long-asparaginase was beneficial in National Cancer Institute standard risk group regarding disease-free survival (hazard ratio: 0.70; P=0.057), but was far less regarding overall survival (hazard ratio: 0.89). The incidence of grade 3-4 infection during consolidation (25.2% versus 14.4%) and late intensification (22.6% versus 15.9%) and the incidence of grade 2-4 allergy were higher in the long-asparaginase arm (30% versus 21%). Prolonged native E.coli asparaginase therapy in consolidation and late intensification for our non-very high risk patients did not improve overall outcome but led to an increase in infections and allergy. This trial was registered at www.clinicaltrials.gov as #NCT00003728. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 79 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 11% |
| Other | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Doctoral Student | 4 | 5% |
| Student > Bachelor | 4 | 5% |
| Other | 7 | 9% |
| Unknown | 42 | 53% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 23% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Nursing and Health Professions | 4 | 5% |
| Neuroscience | 3 | 4% |
| Psychology | 2 | 3% |
| Other | 3 | 4% |
| Unknown | 44 | 56% |